↑ "Human PubMed Reference:" . National Center for Biotechnology Information, U.S. National Library of Medicine .
↑ Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M, Fishlock K, Pagliuca A, Devereux S (September 2002). "Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab" . Blood . 100 (5): 1715–20. PMID 12176892 . Archived from the original on 14 April 2013. Retrieved 23 August 2019 .
↑ Ratzinger G, Reagan JL, Heller G, Busam KJ, Young JW (February 2003). "Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation". Blood . 101 (4): 1422–9. doi :10.1182/blood-2002-04-1093 . PMID 12393688 .
↑ Hale G, Waldmann H (2000). "From Laboratory to Clinic : The Story of CAM PA TH-1" . Methods Mol. Med . 40 : 243–66. doi :10.1385/1-59259-076-4:243 . ISBN 978-1-59259-076-6 . PMID 21337094 .
↑ Piccaluga PP, Agostinelli C, Righi S, Zinzani PL, Pileri SA (April 2007). "Expression of CD52 in peripheral T-cell lymphoma". Haematologica . 92 (4): 566–7. doi :10.3324/haematol.10767 . PMID 17488672 .
↑ Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA (November 2012). "Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial". Lancet . 380 (9856): 1829–39. doi :10.1016/S0140-6736(12)61768-1 . PMID 23122650 .
↑ Cohen, Jeffrey; Coles A; Arnold D (24 November 2012). "Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial" . The Lancet . 380 (9856): 1819–1828. doi :10.1016/S0140-6736(12)61769-3 . PMID 23122652 . Retrieved 28 December 2012 .